newsfilter
← Latest News
GlobeNewswire·

Genenta Announces Pricing of $15.0 Million Registered Direct Offering of American Depositary Shares

GNTA
  • Genenta Science (NASDAQ: GNTA) entered a securities purchase agreement to sell 4,285,715 American Depositary Shares (ADSs) at $3.50 per share.
  • The offering generates gross proceeds of approximately $15.0 million before deducting placement agent fees & offering expenses.
  • Maxim Group LLC acts as the lead placement agent, while Rodman & Renshaw LLC serves as the co-placement agent.
  • Genenta intends to use the net proceeds for working capital & general corporate purposes.
  • The transaction is expected to close on or about October 28, 2025, subject to customary closing conditions.
  • The securities are offered under an effective shelf registration statement on Form F-3 (File No. 333-271901) filed with the SEC.
  • No warrants or other derivative securities were issued in connection with this offering.
  • Genenta is a clinical-stage immuno-oncology company developing Temferon™, a hematopoietic stem cell therapy for solid tumors.
  • The company completed a Phase 1 trial for newly diagnosed Glioblastoma Multiforme (GBM) patients with unmethylated MGMT gene promoters.
  • Genenta has initiated a Phase 1/2a study for metastatic Renal Cell Carcinoma (RCC) that includes combination therapy with immune checkpoint inhibitors.